Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer

NCT05871762 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College Hospital

Phase

Observational

Started

2023-06-04

Last updated

2023-08-28

Condition(s) studied

Rectal Neoplasms

Investigational drug(s) / intervention(s)

Registry study, no specific intervention

Registry study, no specific intervention: Registry study, no specific intervention

Study summary

The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * pathologically confirmed rectal adenocarcinoma * located within 12cm below the anal verge Exclusion Criteria: * diagnosed with distant metastasis * multiple primary colorectal cancers * history of previous malignant tumors * Pregnant or lactating women

Primary outcome measure(s)

3-year OS — 3 years
3-year overall survival

Trial sites (1)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	Beijing Municipality	Recruiting

More Peking Union Medical College Hospital trials in China

Safety and Efficacy Study of PUMCH-E101 Injection in Subjects with RDH12 Retinopathy Recruiting

Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial Starting soon

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer Recruiting

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer Recruiting

Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement Recruiting

Other trials for the same condition

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer Active, not recruiting

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer Active, not recruiting

Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer Recruiting

Reinforced Versus Conventional Anastomosis in Laparoscopic Low Rectal Cancer Resection: A Comparative Study Enrolling by invitation

SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05871762 on ClinicalTrials.gov ↗ ← All trials in China